Order Article Reprints

Orlova A, Rybina A, Medvedeva A, Zelchan R, Bragina O, Tashireva L, Larkina M, Varvashenya R, Lushnikova N, Kanellopoulos P, et al. Phase I Clinical Study with the GRPR-Antagonist [^99mTc]Tc-DB8 for SPECT Imaging of Prostate Cancer: Does the Injected Peptide Mass Make a Difference? Pharmaceutics. 2025; 17(10):1323. https://doi.org/10.3390/pharmaceutics17101323

Orlova, Anna, Anastasia Rybina, Anna Medvedeva, Roman Zelchan, Olga Bragina, Liubov Tashireva, Maria Larkina, Ruslan Varvashenya, Nadejda Lushnikova, Panagiotis Kanellopoulos, and et al. 2025. "Phase I Clinical Study with the GRPR-Antagonist [^99mTc]Tc-DB8 for SPECT Imaging of Prostate Cancer: Does the Injected Peptide Mass Make a Difference?" Pharmaceutics 17, no. 10: 1323. https://doi.org/10.3390/pharmaceutics17101323

Orlova, A., Rybina, A., Medvedeva, A., Zelchan, R., Bragina, O., Tashireva, L., Larkina, M., Varvashenya, R., Lushnikova, N., Kanellopoulos, P., Maina, T., Nock, B. A., Tolmachev, V., & Chernov, V. (2025). Phase I Clinical Study with the GRPR-Antagonist [^99mTc]Tc-DB8 for SPECT Imaging of Prostate Cancer: Does the Injected Peptide Mass Make a Difference? Pharmaceutics, 17(10), 1323. https://doi.org/10.3390/pharmaceutics17101323